Plus, news about Adaptilens:
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA...
Invitation to Participate in STOP-PC Clinical Trial
Oncotelic Announces Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
R&D cost remains essentially unchanged, while continuing expansion of our OT-101 clinical programs through our joint venture (JV)G&A cost significantly lower by over approximately $0.5...